Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Lawrence Nathan Shulman, M.D.

TitleAssociate Professor of Medicine
InstitutionDana-Farber Cancer Institute
DepartmentMedicine
AddressDana-Farber Cancer Institute
Medcn
450 Brookline Ave
Boston MA 02215
Phone617/632-2277
Fax617/632-2260

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Mtonga P, Masamba L, Milner D, Shulman LN, Nyirenda R, Mwafulirwa K. Biopsy case mix and diagnostic yield at a Malawian central hospital. Malawi Med J. 2013 Sep; 25(3):62-4.
    View in: PubMed
  2. Sharma K, Costas A, Damuse R, Hamiltong-Pierre J, Pyda J, Ong CT, Shulman LN, Meara JG. The Haiti Breast Cancer Initiative: Initial Findings and Analysis of Barriers-to-Care Delaying Patient Presentation. J Oncol. 2013; 2013:206367.
    View in: PubMed
  3. Shulman LN, Mamon H, Jacobson JO, Steingisser L, Dodek A, Fallon JA. Partnership between a cancer center and payer: opportunities for improved quality of care and cost reduction. J Oncol Pract. 2013 May 1; 9(3):133-4.
    View in: PubMed
  4. Silva TB, Mauad EC, Carvalho AL, Jacobs LA, Shulman LN. Difficulties in implementing an organized screening program for breast cancer in Brazil with emphasis on diagnostic methods. Rural Remote Health. 2013; 13:2321.
    View in: PubMed
  5. Leblanc TW, Shulman LN, Yu PP, Hirsch BR, Abernethy AP. The ethics of health information technology in oncology: emerging isssues from both local and global perspectives. Am Soc Clin Oncol Educ Book. 2013; 2013:136-42.
    View in: PubMed
  6. Shulman LN. Efficient and effective models for integrating advanced practice professionals into oncology practice. Am Soc Clin Oncol Educ Book. 2013; 2013:377-9.
    View in: PubMed
  7. Keating NL, Landrum MB, Lamont EB, Bozeman SR, Shulman LN, McNeil BJ. Tumor boards and the quality of cancer care. J Natl Cancer Inst. 2013 Jan 16; 105(2):113-21.
    View in: PubMed
  8. Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL, Cox NJ, Dolan ME. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2013 Jan 15; 19(2):491-9.
    View in: PubMed
  9. Weingart SN, Cleary A, Scullion B, Morway L, Phantumvanit V, Stuver SO, Shulman LN, Connors JM. Comparing clinicians' use of an anticoagulation management service and usual care in ambulatory oncology. J Oncol Pharm Pract. 2013 Sep; 19(3):237-45.
    View in: PubMed
  10. Miriovsky BJ, Shulman LN, Abernethy AP. Importance of health information technology, electronic health records, and continuously aggregating data to comparative effectiveness research and learning health care. J Clin Oncol. 2012 Dec 1; 30(34):4243-8.
    View in: PubMed
  11. Weingart SN, Mattsson T, Zhu J, Shulman LN, Hassett M. Improving electronic oral chemotherapy prescription: can we build a safer system? J Oncol Pract. 2012 Nov; 8(6):e168-73.
    View in: PubMed
  12. Sharma K, Costas A, Shulman LN, Meara JG. A systematic review of barriers to breast cancer care in developing countries resulting in delayed patient presentation. J Oncol. 2012; 2012:121873.
    View in: PubMed
  13. Kahn MJ, Ma AD, Shulman LN. Update in hematology and medical oncology: evidence published in 2011. Ann Intern Med. 2012 Aug 21; 157(4):276-83.
    View in: PubMed
  14. Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res. 2012 Sep 15; 18(18):5099-109.
    View in: PubMed
  15. Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C. Six cycles of Doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: cancer and leukemia group B 40101. J Clin Oncol. 2012 Nov 20; 30(33):4071-6.
    View in: PubMed
  16. Knaul FM, Shulman LN, Gralow J, Quick J, Bhadelia A, Frenk J. Improving pathology for better cancer care and control in countries of low and middle income. Lancet. 2012 Jun 2; 379(9831):2052.
    View in: PubMed
  17. Gatzos LC, Barbetti S, Bas-Davis S, Mailman A, Brzezinski P, Ruseau P, Barr Vermilya H, Schott D, Marston E, Sturtevant OJ, Ritz J, Shulman LN. Development and implementation of a computerized system for collection, processing, and administration of cellular therapy products. J Oncol Pract. 2012 Sep; 8(5):262-6.
    View in: PubMed
  18. Solin LJ, Gray R, Goldstein LJ, Recht A, Baehner FL, Shak S, Badve S, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW, Sparano JA. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat. 2012 Jul; 134(2):683-92.
    View in: PubMed
  19. Peppercorn J, Shapira I, Deshields T, Kroetz D, Friedman P, Spears P, Collyar DE, Shulman LN, Dressler L, Bertagnolli MM. Ethical aspects of participation in the database of genotypes and phenotypes of the National Center for Biotechnology Information: the Cancer and Leukemia Group B Experience. Cancer. 2012 Oct 15; 118(20):5060-8.
    View in: PubMed
  20. Landrum MB, Keating NL, Lamont EB, Bozeman SR, Krasnow SH, Shulman L, Brown JR, Earle CC, Rabin M, McNeil BJ. Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare. J Clin Oncol. 2012 Apr 1; 30(10):1072-9.
    View in: PubMed
  21. Shulman LN. Bringing Cancer Care to Those who Don't Have It. Narrat Inq Bioeth. 2012; 2(2):E10-2.
    View in: PubMed
  22. Weingart SN, Li JW, Zhu J, Morway L, Stuver SO, Shulman LN, Hassett MJ. US Cancer Center Implementation of ASCO/Oncology Nursing Society Chemotherapy Administration Safety Standards. J Oncol Pract. 2012 Jan; 8(1):7-12.
    View in: PubMed
  23. Ettinger DS, Agulnik M, Cates JM, Cristea M, Denlinger CS, Eaton KD, Fidias PM, Gierada D, Gockerman JP, Handorf CR, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Shulman LN, Smerage JB, Varadhachary GR, Zager JS, Zhen WK. Occult primary. J Natl Compr Canc Netw. 2011 Dec; 9(12):1358-95.
    View in: PubMed
  24. Stuver SO, Zhu J, Simchowitz B, Hassett MJ, Shulman LN, Weingart SN. Identifying women at risk of delayed breast cancer diagnosis. Jt Comm J Qual Patient Saf. 2011 Dec; 37(12):568-75.
    View in: PubMed
  25. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez EA, Shulman LN, Martino S, Davidson NE, Kenny PA, Sledge GW, Gray R. Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. Clin Cancer Res. 2011 Nov 15; 17(22):7194-203.
    View in: PubMed
  26. Beckjord EB, Rechis R, Nutt S, Shulman L, Hesse BW. What Do People Affected by Cancer Think About Electronic Health Information Exchange? Results From the 2010 LIVESTRONG Electronic Health Information Exchange Survey and the 2008 Health Information National Trends Survey. J Oncol Pract. 2011 Jul; 7(4):237-41.
    View in: PubMed
  27. Keating NL, Landrum MB, Lamont EB, Bozeman SR, Krasnow SH, Shulman LN, Brown JR, Earle CC, Oh WK, Rabin M, McNeil BJ. Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study. Ann Intern Med. 2011 Jun 7; 154(11):727-36.
    View in: PubMed
  28. Neuss MN, Flamm C, Shulman LN, Tomkins JE, Ward JC. Report on the ASCO 2010 Provider-Payer Initiative Meeting. J Oncol Pract. 2011 May; 7(3):136-40.
    View in: PubMed
  29. Harford JB, Otero IV, Anderson BO, Cazap E, Gradishar WJ, Gralow JR, Kane GM, Niëns LM, Porter PL, Reeler AV, Rieger PT, Shockney LD, Shulman LN, Soldak T, Thomas DB, Thompson B, Winchester DP, Zelle SG, Badwe RA. Problem solving for breast health care delivery in low and middle resource countries (LMCs): consensus statement from the Breast Health Global Initiative. Breast. 2011 Apr; 20 Suppl 2:S20-9.
    View in: PubMed
  30. Shulman LN, Willett W, Sievers A, Knaul FM. Breast cancer in developing countries: opportunities for improved survival. J Oncol. 2010; 2010:595167.
    View in: PubMed
  31. Bunnell CA, Shulman LN. Will we be able to care for cancer patients in the future? Oncology (Williston Park). 2010 Dec; 24(14):1343-8.
    View in: PubMed
  32. Bunnell CA, Weingart SN, Swanson S, Mamon HJ, Shulman LN. Models of multidisciplinary cancer care: physician and patient perceptions in a comprehensive cancer center. J Oncol Pract. 2010 Nov; 6(6):283-8.
    View in: PubMed
  33. Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, Atun R, Blayney D, Chen L, Feachem R, Gospodarowicz M, Gralow J, Gupta S, Langer A, Lob-Levyt J, Neal C, Mbewu A, Mired D, Piot P, Reddy KS, Sachs JD, Sarhan M, Seffrin JR. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010 Oct 2; 376(9747):1186-93.
    View in: PubMed
  34. Weingart SN, Toro J, Spencer J, Duncombe D, Gross A, Bartel S, Miransky J, Partridge A, Shulman LN, Connor M. Medication errors involving oral chemotherapy. Cancer. 2010 May 15; 116(10):2455-64.
    View in: PubMed
  35. Drews RE, Shulman LN. Update in hematology and oncology. Ann Intern Med. 2010 May 18; 152(10):655-62.
    View in: PubMed
  36. Carlson JW, Lyon E, Walton D, Foo WC, Sievers AC, Shulman LN, Farmer P, Nosé V, Milner DA. Partners in pathology: a collaborative model to bring pathology to resource poor settings. Am J Surg Pathol. 2010 Jan; 34(1):118-23.
    View in: PubMed
  37. Buswell LA, Ponte PR, Shulman LN. Provider practice models in ambulatory oncology practice: analysis of productivity, revenue, and provider and patient satisfaction. J Oncol Pract. 2009 Jul; 5(4):188-92.
    View in: PubMed
  38. Shulman LN, Jacobs LA, Greenfield S, Jones B, McCabe MS, Syrjala K, Diller L, Shapiro CL, Marcus AC, Campbell M, Santacroce S, Kagawa-Singer M, Ganz PA. Cancer care and cancer survivorship care in the United States: will we be able to care for these patients in the future? J Oncol Pract. 2009 May; 5(3):119-23.
    View in: PubMed
  39. Weingart SN, Saadeh MG, Simchowitz B, Gandhi TK, Nekhlyudov L, Studdert DM, Puopolo AL, Shulman LN. Process of care failures in breast cancer diagnosis. J Gen Intern Med. 2009 Jun; 24(6):702-9.
    View in: PubMed
  40. Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 1; 14(23):7871-7.
    View in: PubMed
  41. Ettinger DS, Agulnik M, Cristea M, Eaton K, Fidias PM, Gockerman JP, Hameed O, Handorf C, Harris EI, Jacobs CD, Javle M, Khushalani NI, Kvols L, Lenzi R, Lewis NL, Rashid A, Saltz L, Shulman LN, Zager JS, Zhen W. Occult primary. J Natl Compr Canc Netw. 2008 Nov; 6(10):1026-60.
    View in: PubMed
  42. Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol. 2008 Sep 1; 26(25):4092-9.
    View in: PubMed
  43. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW, Perez EA, Shulman LN, Martino S, Sparano JA. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008 Sep 1; 26(25):4063-71.
    View in: PubMed
  44. Bansal A, Binkert CA, Robinson MK, Shulman LN, Pellerin L, Davison B. Impact of quality management monitoring and intervention on central venous catheter dysfunction in the outpatient chemotherapy infusion setting. J Vasc Interv Radiol. 2008 Aug; 19(8):1171-5.
    View in: PubMed
  45. Hwang D, Shakir N, Limann B, Sison C, Kalra S, Shulman L, Souza Ade C, Greenberg H. Association of sleep-disordered breathing with postoperative complications. Chest. 2008 May; 133(5):1128-34.
    View in: PubMed
  46. Shulman LN, Hitt RA, Ferry JA. Case records of the Massachusetts General Hospital. Case 4-2008. A 33-year-old pregnant woman with swelling of the left breast and shortness of breath. N Engl J Med. 2008 Jan 31; 358(5):513-23.
    View in: PubMed
  47. Weingart SN, Cleary A, Seger A, Eng TK, Saadeh M, Gross A, Shulman LN. Medication reconciliation in ambulatory oncology. Jt Comm J Qual Patient Saf. 2007 Dec; 33(12):750-7.
    View in: PubMed
  48. Tolaney SM, Colson YL, Gill RR, Schulte S, Duggan MM, Shulman LN, Winer EP. Sarcoidosis mimicking metastatic breast cancer. Clin Breast Cancer. 2007 Oct; 7(10):804-10.
    View in: PubMed
  49. Lin NU, Parker LM, Come SE, Burstein HJ, Haldoupis M, Ryabin N, Gelman R, Winer EP, Shulman LN. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs. 2007 Aug; 25(4):369-75.
    View in: PubMed
  50. Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol. 2007 Jan 20; 25(3):313-8.
    View in: PubMed
  51. Weingart SN, Flug J, Brouillard D, Morway L, Partridge A, Bartel S, Shulman LN, Connor M. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ. 2007 Feb 24; 334(7590):407.
    View in: PubMed
  52. Shulman, LN. Multidisciplinary breast cancer care: perspectives from team members at Dana-Farber Cancer Institute/Multidisciplinary breast cancer care from the point of view of the medical oncologist. Am J Hematol Oncol. 2007; 6:17-18.
  53. Balogh GA, Mailo DA, Corte MM, Roncoroni P, Nardi H, Vincent E, Martinez D, Cafasso ME, Frizza A, Ponce G, Vincent E, Barutta E, Lizarraga P, Lizarraga G, Monti C, Paolillo E, Vincent R, Quatroquio R, Grimi C, Maturi H, Aimale M, Spinsanti C, Montero H, Santiago J, Shulman L, Rivadulla M, Machiavelli M, Salum G, Cuevas MA, Picolini J, Gentili A, Gentili R, Mordoh J. Mutant p53 protein in serum could be used as a molecular marker in human breast cancer. Int J Oncol. 2006 Apr; 28(4):995-1002.
    View in: PubMed
  54. Hassett MJ, Shulman LN. A tale of two taxanes: Docetaxel or paclitaxel for advanced or metastatic breast cancer. Am J Oncol Rev. 2006; 5:162-4.
  55. Sundaram R, Shulman L, Fein AM. Trends in tobacco use. Clin Occup Environ Med. 2006; 5(1):1-7, vii.
    View in: PubMed
  56. Gandhi TK, Bartel SB, Shulman LN, Verrier D, Burdick E, Cleary A, Rothschild JM, Leape LL, Bates DW. Medication safety in the ambulatory chemotherapy setting. Cancer. 2005 Dec 1; 104(11):2477-83.
    View in: PubMed
  57. Bellon JR, Come SE, Gelman RS, Henderson IC, Shulman LN, Silver BJ, Harris JR, Recht A. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol. 2005 Mar 20; 23(9):1934-40.
    View in: PubMed
  58. Ettinger DS, Arnoletti JP, Gockerman JP, Handorf C, Havlin KA, Jacobs CD, Javle M, Kvols L, Lenzi R, Rashid A, Rhoades CA, Ridge JA, Saltz L, Shulman LN, Sondak VK, Thompson JA, Twardowski P, Zhen W. Occult primary cancer clinical practice guidelines. J Natl Compr Canc Netw. 2005 Mar; 3(2):214-33.
    View in: PubMed
  59. Pizziferri L, Kittler AF, Volk LA, Shulman LN, Kessler J, Carlson G, Michaelidis T, Bates DW. Impact of an Electronic Health Record on oncologists' clinic time. AMIA Annu Symp Proc. 2005; 1083.
    View in: PubMed
  60. Shulman L, Ost D. Managing infection in the critical care unit: how can infection control make the ICU safe? Crit Care Clin. 2005 Jan; 21(1):111-28, ix.
    View in: PubMed
  61. Sundaram R, Shulman L, Fein AM. Trends in tobacco use. Med Clin North Am. 2004 Nov; 88(6):1391-7, ix.
    View in: PubMed
  62. McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, Bartel S, Fuchs CS. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol. 2004 Oct; 27(5):485-8.
    View in: PubMed
  63. Bellon JR, Shulman LN, Come SE, Li X, Gelman RS, Silver BJ, Harris JR, Recht A. A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma. Cancer. 2004 Apr 1; 100(7):1358-64.
    View in: PubMed
  64. Lukanich JM, Sugarbaker DJ, Shulman LN. Malignant effusions. . Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the breast. 2004; 1261-72.
  65. Mentzer SJ, Sugarbaker DJ, Shulman LN. Management of Discrete Pulmonary Nodules. Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the breast. 2004; 1273-8.
  66. Nadler E, Shulman LN. High-dose, stem cell supported chemotherapy vs conventional chemotherapy as treatment for patients with locally advanced breast cancer: Do randomized trials settle the debate?. Am J Oncol Rev. 2004; 3:36-38.
  67. Canellos GP, Gollub J, Neuberg D, Mauch P, Shulman LN. Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Ann Oncol. 2003 Feb; 14(2):268-72.
    View in: PubMed
  68. Ponte PR, Conlin G, Conway JB, Grant S, Medeiros C, Nies J, Shulman L, Branowicki P, Conley K. Making patient-centered care come alive: achieving full integration of the patient's perspective. J Nurs Adm. 2003 Feb; 33(2):82-90.
    View in: PubMed
  69. Bellon JR, Shulman LN. Breast-conserving surgery vs mastectomy: How much data do we need to gain widespread acceptance and utilization? (commentary). Am J Oncol Rev. 2003; 2:42-4.
  70. Hassett MJ, Shulman LN. Dose-dense chemotherapy as adjuvant therapy for node-positive breast cancer: Does this work and why?. Am J Oncol Rev. 2003; 2:378-81.
  71. Shulman LN. Lessons learned from the MD Anderson adjuvant trials exploring sequential chemotherapy. Am J Oncol Rev. 2003; 2:454-5.
  72. Eder JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 2002 Sep 15; 20(18):3772-84.
    View in: PubMed
  73. Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, Kirn DH, O'Neill V, Siddiqui N, Seiden MV, Kaye SB. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol. 2002 Mar 15; 20(6):1562-9.
    View in: PubMed
  74. Shulman LN, Cady B, Kopans DB, Oratz R. Mammography screening for breast cancer: The data behind the debate. Medical Crossfire. 2002; 4:34-45.
  75. Shulman LN. Neoadjuvant chemotherapy followed by mastectomy: Who need radiation? (commentary). Am J Oncol Rev. 2002; 1:20-1.
  76. Shulman LN, Cutler CS. Non-gynecologic cancer in pregnancy. Carlson K, Eisenstat SA, eds. Primary care of women. 2002; 540-5.
  77. Shulman LN. Chemotherapy in the treatment of patients with metastatic breast cancer: High-dose, low-dose - What have we accomplished? (commentary). Am J Oncol Rev. 2002; 1:169-70.
  78. Shulman LN. What is the ideal duration of adjuvant therapy for primary breast cancer: are four cycles of cyclophosphamide and doxorubicin enough? Curr Oncol Rep. 2001 Nov; 3(6):523-8.
    View in: PubMed
  79. Bunnell CA, Supko JG, Eder JP, Clark JW, Lynch TJ, Kufe DW, Shulman LN. Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies. Cancer Chemother Pharmacol. 2001 Nov; 48(5):347-55.
    View in: PubMed
  80. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.
    View in: PubMed
  81. Shinnar S, Rapin I, Arnold S, Tuchman RF, Shulman L, Ballaban-Gil K, Maw M, Deuel RK, Volkmar FR. Language regression in childhood. Pediatr Neurol. 2001 Mar; 24(3):183-9.
    View in: PubMed
  82. Shoulson I, Penney J, McDermott M, Schwid S, Kayson E, Chase T, Fahn S, Greenamyre JT, Lang A, Siderowf A, Pearson N, Harrison M, Rost E, Colcher A, Lloyd M, Matthews M, Pahwa R, McGuire D, Lew MF, Schuman S, Marek K, Broshjeit S, Factor S, Brown D, Feigin A, Mazurkiewicz J, Ford B, Jennings D, Dilllon S, Comella C, Blasucci L, Janko K, Shulman L, Wiener W, Bateman-Rodriguez D, Carrion A, Suchowersky O, Lafontaine AL, Pantella C, Siemers E, Belden J, Davies R, Lannon M, Grimes D, Gray P, Martin W, Kennedy L, Adler C, Newman S, Hammerstad J, Stone C, Lewitt P, Bardram K, Mistura K, Miyasaki J, Johnston L, Cha JH, Tennis M, Panniset M, Hall J, Tetrud J, Friedlander J, Hauser R, Gauger L, Rodnitzky R, Deleo A, Dobson J, Seeberger L, Dingmann C, Tarsy D, Ryan P, Elmer L, Ruzicka D, Stacy M, Brewer M, Locke B, Baker D, Casaceli C, Day D, Florack M, Hodgeman K, Laroia N, Nobel R, Orme C, Rexo L, Rothenburgh K, Sulimowicz K, Watts A, Wratni E, Tariot P, Cox C, Leventhal C, Alderfer V, Craun AM, Frey J, McCree L, McDermott J, Cooper J, Holdich T, Read B. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology. 2001 Feb 27; 56(4):455-62.
    View in: PubMed
  83. Jacobson JO, Grossbard M, Shulman LN, Neuberg D. CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis. Clin Lymphoma. 2000 Dec; 1(3):211-7; discussion 218.
    View in: PubMed
  84. Sternberg DW, Aird W, Neuberg D, Thompson L, MacNeill K, Amrein P, Shulman LN. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen. Cancer. 2000 May 1; 88(9):2037-41.
    View in: PubMed
  85. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000 Mar; 18(6):1212-9.
    View in: PubMed
  86. Ramaswamy S, Osteen RT, Shulman LN. Metastatic cancer from an unknown primary site. Lenhard Jr RE, Osteen RT, Gansler T, eds. The American Cancer Society's Clinical Oncology. 2000; 711-9.
  87. Shulman LN, Sugarbaker DJ. Malignant effusions. Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the breast. 2000; 893-900.
  88. Miller KD, Picus J, Blanke C, John W, Clark J, Shulman LN, Thornton D, Rowinsky E, Loehrer PJ. Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol. 2000 Jan; 11(1):101-3.
    View in: PubMed
  89. Shulman L, Mahallati H, Gray R. Soft-tissue case 30. Presentation. Pelvic trauma: detection of active bleeding by computed tomography. Can J Surg. 1999 Dec; 42(6):413, 420.
    View in: PubMed
  90. Dubey A, Recht A, Come SE, Gelman RS, Silver B, Harris JR, Shulman LN. Concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study. Int J Radiat Oncol Biol Phys. 1999 Nov 1; 45(4):877-84.
    View in: PubMed
  91. Gray RR, Sadler DJ, Shulman L, Saliken JC, So CB. Should anticoagulant therapy be stopped or reversed before venous intervention? Can Assoc Radiol J. 1999 Oct; 50(5):306-9.
    View in: PubMed
  92. Hardenbergh PH, Recht A, Gollamudi S, Come SE, Hayes DF, Shulman LN, O'Neill A, Gelman RS, Silver B, Harris JR. Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer. Int J Radiat Oncol Biol Phys. 1999 Aug 1; 45(1):69-72.
    View in: PubMed
  93. Shulman LN, Buswell L, Riese N, Doherty N, Loeffler JS, von Roemeling RW, Coleman CN. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. Int J Radiat Oncol Biol Phys. 1999 May 1; 44(2):349-53.
    View in: PubMed
  94. Shulman LN. . Is anaplastic large cell lymphoma (ALCL) clinically distinct from diffuse large B cell lymphoma?. Mason DY and Harris NL, eds. Human lymphoma: clniical implications of the REAL classification. 1999; 39:0-7.
  95. Shulman LN. . The acute leukemias. Irwin RS, Cerra FB, Rippe JM, eds. Irwin and Rippe's Intensive care medicine. 1999; 1391-5.
  96. Abner AL, Collins L, Peiro G, Recht A, Come S, Shulman LN, Silver B, Nixon A, Harris JR, Schnitt SJ, Connolly JL. Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma. Cancer. 1998 Dec 15; 83(12):2502-8.
    View in: PubMed
  97. Shulman LN, Tarbell NJ, Storen E, Marcus K, Mauch PM. Low-dose total body irradiation and G-CSF without hematopoietic stem cell support in the treatment of relapsed or refractory acute myelogenous leukemia (AML), or AML in second or subsequent remission. Int J Radiat Oncol Biol Phys. 1998 Dec 1; 42(5):1113-7.
    View in: PubMed
  98. Smith D, Shaffer K, Kirn D, Canellos GP, Mauch PM, Shulman LN. Mediastinal large cell lymphoma: prognostic significance of CT findings at presentation and after treatment. Oncology. 1998 Jul-Aug; 55(4):284-8.
    View in: PubMed
  99. Bunnell CA, Thompson L, Buswell L, Berkowitz R, Muto M, Sheets E, Shulman LN. A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. Cancer. 1998 Feb 1; 82(3):561-6.
    View in: PubMed
  100. Gage I, Schnitt SJ, Recht A, Abner A, Come S, Shulman LN, Monson JM, Silver B, Harris JR, Connolly JL. Skin recurrences after breast-conserving therapy for early-stage breast cancer. J Clin Oncol. 1998 Feb; 16(2):480-6.
    View in: PubMed
  101. Eder JP, Supko JG, Lynch T, Bryant M, Vosburgh E, Shulman LN, Xu G, Kufe DW. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clin Cancer Res. 1998 Feb; 4(2):317-24.
    View in: PubMed
  102. Sehn LH, Antin JH, Shulman LN, Mauch P, Elias A, Kadin ME, Wheeler C. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood. 1998 Jan 15; 91(2):717-23.
    View in: PubMed
  103. Dubey AK, Recht A, Come S, Shulman L, Harris J. Why and how to combine chemotherapy and radiation therapy in breast cancer patients. Recent Results Cancer Res. 1998; 152:247-54.
    View in: PubMed
  104. Shulman LN. Hematologic malignancies. Schiffman FJ, ed. Hematolgoic pathophysiology. 1998; 291-317.
  105. Wong JS, Recht A, Beard CJ, Busse PM, Cady B, Chaffey JT, Come S, Fam S, Kaelin C, Lingos TI, Nixon AJ, Shulman LN, Troyan S, Silver B, Harris JR. Treatment outcome after tangential radiation therapy without axillary dissection in patients with early-stage breast cancer and clinically negative axillary nodes. Int J Radiat Oncol Biol Phys. 1997 Nov 1; 39(4):915-20.
    View in: PubMed
  106. Bodis S, Kraus MD, Pinkus G, Silver B, Kadin ME, Canellos GP, Shulman LN, Tarbell NJ, Mauch PM. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol. 1997 Sep; 15(9):3060-6.
    View in: PubMed
  107. Dees EC, Shulman LN, Souba WW, Smith BL. Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? An algorithm for assessment of impact of axillary dissection. Ann Surg. 1997 Sep; 226(3):279-86; discussion 286-7.
    View in: PubMed
  108. Hughes-Davies L, Tarbell NJ, Coleman CN, Silver B, Shulman LN, Linggood R, Canellos GP, Mauch PM. Stage IA-IIB Hodgkin's disease: management and outcome of extensive thoracic involvement. Int J Radiat Oncol Biol Phys. 1997 Sep 1; 39(2):361-9.
    View in: PubMed
  109. Elias AD, Skarin AT, Leong T, Mentzer S, Strauss G, Lynch T, Shulman L, Jacobs C, Abner A, Baldini EH, Frei E, Sugarbaker DJ. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer. 1997 May; 17(1):147-61.
    View in: PubMed
  110. Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol. 1997 Apr; 15(4):1631-7.
    View in: PubMed
  111. Shulman LN, Braunwald E, Rosenthal DS. Hematologic-oncologic disorders and heart disease. Braunwald E, ed. Heart Disease: A textbook of cardiovascular medicine. 1997; 1786-1808.
  112. Eder JP, Rubin E, Stone R, Bryant M, Xu G, Supko J, Kinchla N, Lynch T, Hurwitz S, Rodriguez D, Shapiro C, Toppmeyer D, Grossbard M, Vosburg E, Huberman M, Schnipper L, Shulman L, Kufe DW. Trials of 9-amino-20(S)-camptothecin in Boston. Ann N Y Acad Sci. 1996 Dec 13; 803:247-55.
    View in: PubMed
  113. Shaffer K, Smith D, Kirn D, Kaplan W, Canellos G, Mauch P, Shulman LN. Primary mediastinal large-B-cell lymphoma: radiologic findings at presentation. AJR Am J Roentgenol. 1996 Aug; 167(2):425-30.
    View in: PubMed
  114. Recht A, Come SE, Henderson IC, Gelman RS, Silver B, Hayes DF, Shulman LN, Harris JR. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med. 1996 May 23; 334(21):1356-61.
    View in: PubMed
  115. Mauch PM, Kalish LA, Marcus KC, Coleman CN, Shulman LN, Krill E, Come S, Silver B, Canellos GP, Tarbell NJ. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood. 1996 May 1; 87(9):3625-32.
    View in: PubMed
  116. Recht A, Come SE, Henderson IC, Gelman RS, Silver B, Hayes DF, Shulman LN, Harris JR. Five-year results of a randomized trial testing sequencing of chemotherapy and radiation therapy following conservative surgery for patients with early-stage breast cancer. N Engl J Med. 1996; 334:1356-61.
  117. Shaffer K, Smith D, Kirn D, Kaplan W, Canellos G, Mauch P, Shulman LN. Primary mediastinal Large B-cell lymphoma: Radiologic findings at presentation. Am J Roentgenol. 1996; 167:425-30.
  118. Teich JM, Schmiz JL, O'Connell EM, Fanikos J, Marks PW, Shulman LN. An information system to improve the safety and efficiency of chemotherapy ordering. Proc AMIA Annu Fall Symp. 1996; 498-502.
    View in: PubMed
  119. Shulman LN, Lichter AS, Allison MA, Bitran JD, Davidson NE, Grunberg SM, Halberg FE, Lewis BJ, Link MP, Mazanet R, Offit K, Ozer H, Presant CA, Runowicz CD, Seardino PT, Schnipper LE, Stovall EL, Vogelzang NJ, Wade JL, Weber BL, Wiernik PH. American Society of Clinical Oncology. Special Article: Funding for clinical (patient-oriented) oncology research: Current status and recommendations for improvement. J Clin Oncol. 1996; 14:666-70.
  120. Shulman LN. The acute leukemias. Rippe JM, Irwin RS, Fink MP, Cerra FB, eds. Intensive care medicine. 1996; 1432-7.
  121. Gore SM, Shulman LN, Osteen RT. Metastatic cancer from an unknown primary site. Osteen RT, ed. Cancer Manual. 1996; 596-607.
  122. Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol. 1995 Dec; 13(12):2916-23.
    View in: PubMed
  123. Comiter CV, Benson CJ, Capelouto CC, Kantoff P, Shulman L, Richie JP, Loughlin KR. Nonpalpable intratesticular masses detected sonographically. J Urol. 1995 Oct; 154(4):1367-9.
    View in: PubMed
  124. Benjamin RJ, Linsley L, Axelrod JD, Churchill WH, Sieff C, Shulman LN, Elias A, Ayash L, Malachowski ME, Uhl L, et al. The collection and evaluation of peripheral blood progenitor cells sufficient for repetitive cycles of high-dose chemotherapy support. Transfusion. 1995 Oct; 35(10):837-44.
    View in: PubMed
  125. Shulman LN, Mauch PM. Current role of radiotherapy in Hodgkin's and non-Hodgkin's lymphoma. Curr Opin Oncol. 1995 Sep; 7(5):421-5.
    View in: PubMed
  126. Strauss GM, Lynch TJ, Elias AD, Jacobs C, Kwiatkowski DJ, Shulman LN, Carey RW, Grossbard ML, Jauss S, Sugarbaker DJ, et al. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer. Semin Oncol. 1995 Aug; 22(4 Suppl 9):70-4.
    View in: PubMed
  127. Mauch PM, Kalish LA, Marcus KC, Shulman LN, Krill E, Tarbell NJ, Silver B, Weinstein H, Come S, Canellos GP, Coleman CN. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am. 1995 May-Jun; 1(1):33-42.
    View in: PubMed
  128. Mauch PM, Canellos GP, Shulman LN, Silver B, Tarbell NJ, Come S, Rabin MS, Coleman CN. Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's disease: preliminary results of a prospective trial. J Clin Oncol. 1995 Apr; 13(4):947-52.
    View in: PubMed
  129. Shulman LN, Sugarbaker DJ. Malignant effusions. Harris JR, Lippman ME, Morrow M, Hellman S, eds. Diseases of the breast. 1995; 833-40.
  130. Shulman LN. Plasma cell diseases and related disorders. Handin RI, Lux SE, Stossel TP, eds. Blood: Principles and practice of hematology. 1995; 885-913.
  131. Shulman LN. Non-gynecologic cancer. Carlson K, Eisenstat SA, eds. The primary care of women. 1995; 368-73.
  132. Lee SJ, Shulman LN. Acute leukemia in adults. Rakel RE ed. Conn's current therapy. 1995; 359-64.
  133. Marks PW, Shulman LN. The diagnosis and management of multiple myeloma. Compr Ther. 1995; 21(1):7-12.
    View in: PubMed
  134. Marcus KC, Kalish LA, Coleman CN, Shulman LN, Rosenthal DS, Canellos GP, Mauch PM. Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy. J Clin Oncol. 1994 Dec; 12(12):2567-72.
    View in: PubMed
  135. Tepler I, Elias A, Kalish L, Shulman L, Strauss G, Skarin A, Lynch T, Levitt D, Resta D, Demetri G, et al. Effect of recombinant human interleukin-3 on haematological recovery from chemotherapy-induced myelosuppression. Br J Haematol. 1994 Aug; 87(4):678-86.
    View in: PubMed
  136. Shulman LN, Buswell L, Goodman H, Muto M, Berkowitz R, Teicher B, Kusumoto T, Hurwitz SJ, Kalish LA, Coleman CN. Phase I pharmacokinetic study of the hypoxic cell sensitizer etanidazole with carboplatin and cyclophosphamide in the treatment of advanced ovarian cancer. Int J Radiat Oncol Biol Phys. 1994 Jun 15; 29(3):545-8.
    View in: PubMed
  137. Shulman LN, Buswell L, Kalish LA, Coleman CN. Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study. Int J Radiat Oncol Biol Phys. 1994 Jun 15; 29(3):541-3.
    View in: PubMed
  138. Doherty N, Hancock SL, Kaye S, Coleman CN, Shulman L, Marquez C, Mariscal C, Rampling R, Senan S, Roemeling RV. Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation. Int J Radiat Oncol Biol Phys. 1994 May 15; 29(2):379-82.
    View in: PubMed
  139. Lynch TJ, Kalish LA, Kass F, Strauss G, Elias A, Skarin A, Shulman L, Sugarbaker D, Frei E. Continuous-infusion cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer. Cancer. 1994 Feb 15; 73(4):1171-6.
    View in: PubMed
  140. Lynch TJ, Kalish L, Strauss G, Elias A, Skarin A, Shulman LN, Posner M, Frei E. Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol. 1994 Feb; 12(2):347-52.
    View in: PubMed
  141. Ballen KK, Gilliland DG, Kalish LA, Shulman LN. Bone marrow dysplasia in patients with newly diagnosed acute myelogenous leukemia does not correlate with history of myelodysplasia or with remission rate and survival. Cancer. 1994 Jan 15; 73(2):314-21.
    View in: PubMed
  142. Lynch TJ, Kalish LA, Kass F, Strauss G, Elias A, Skarin A, Shulman L, Sugarbaker D, Frei E. Continuous infusion cisplatin, 5-FU and leucovorin (PFL) for advanced non-small cell lung cancer. Cancer. 1994; 73:1171-6.
  143. Uematsu M, Tarbell NJ, Silver B, Coleman CN, Rosenthal DS, Shulman LN, Canellos G, Weinstein H, Mauch P. Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin disease in relapse after initial combination chemotherapy. Cancer. 1993 Jul 1; 72(1):207-12.
    View in: PubMed
  144. Lynch TJ, Kass F, Kalish LA, Elias AD, Strauss G, Shulman LN, Sugarbaker DJ, Skarin A, Frei E. Cisplatin, 5-fluorouracil, and etoposide for advanced non-small cell lung cancer. Cancer. 1993 May 15; 71(10):2953-7.
    View in: PubMed
  145. Shulman LN, Frisard B, Antin JH, Wheeler C, Pinkus G, Magauran N, Mauch P, Nobles E, Mashal R, Canellos G, et al. Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome. J Clin Oncol. 1993 May; 11(5):937-42.
    View in: PubMed
  146. Healey EA, Tarbell NJ, Kalish LA, Silver B, Rosenthal DS, Marcus K, Shulman LN, Coleman CN, Canellos G, Weinstein H, et al. Prognostic factors for patients with Hodgkin disease in first relapse. Cancer. 1993 Apr 15; 71(8):2613-20.
    View in: PubMed
  147. Uematsu M, Bornstein BA, Recht A, Abner A, Come SE, Shulman LN, Silver B, Harris JR. Long-term results of post-operative radiation therapy following mastectomy with or without chemotherapy in stage I-III breast cancer. Int J Radiat Oncol Biol Phys. 1993 Apr 2; 25(5):765-70.
    View in: PubMed
  148. Kelsey KT, Caggana-Aviles M, Mauch P, Coleman CN, Shulman LN, Liber HL. Mutagenesis after therapy for Hodgkin's disease. Hematol Oncol Clin North Am. 1993 Apr; 7(2):353-67.
    View in: PubMed
  149. Shulman LN. The biology of alkylating-agent cellular injury. Hematol Oncol Clin North Am. 1993 Apr; 7(2):325-35.
    View in: PubMed
  150. Shulman LN. Normocytic anemias. Robinson SH, Reich PR, eds. Hematology: Pathophysiologic basis for clinical practice. 1993; 109-26.
  151. Abner AL, Recht A, Eberlein T, Come S, Shulman L, Hayes D, Connolly JL, Schnitt SJ, Silver B, Harris JR. Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol. 1993 Jan; 11(1):44-8.
    View in: PubMed
  152. Antin JH, Shulman LN, editors. . Therapy related second malignancies. Hematol Oncol Clin North Am. 1993.
  153. Kirn D, Mauch P, Shaffer K, Pinkus G, Shipp MA, Kaplan WD, Tung N, Wheeler C, Beard CJ, Canellos GP, Shulman LN. Large cell and immunoblastic lymphoma of the mediastinum: Prognostic features and treatment outcome in 57 patients. J Clin Oncol. 1993; 11:1336-43.
  154. Shulman LN. White blood cell disorders. Braunwald E, Rose BD, eds. Intensive review of internal medicine. 1993; 32-46.
  155. Eng C, Farraye FA, Shulman LN, Peppercorn MA, Krauss CM, Connors JM, Stone RM. The association between the myelodysplastic syndromes and Crohn disease. Ann Intern Med. 1992 Oct 15; 117(8):661-2.
    View in: PubMed
  156. Kaye JA, Shulman LN. Screening program for colorectal cancer: effect on stage distribution. HMO Pract. 1992 Sep; 6(3):13-5.
    View in: PubMed
  157. Shulman LN. Primary breast cancer with negative axillary nodes: prognosis and therapy. Brigham and Women's Hospital: Medical Update. 1992; 4:1-5.
  158. Kaye JA, Shulman LN. Screening program for colorectal cancer: Effect on stage distribution. HMO Practice. 1992; 6:13-5.
  159. Eng C, Farraye FA, Shulman LN, Peppercorn MA, Krauss CM, Connors JM, Stone RM. The association of myelodysplastic syndrome with Crohn's disease. Ann Intern Med. 1992; 117:661-2.
  160. Kaye JA, Shulman LN. Screening program for colorectal cancer: participation and follow up. HMO Pract. 1991 Sep-Oct; 5(5):168-70.
    View in: PubMed
  161. Wheeler CA, Shulman LN, Ervin T, Come SE, Schnipper LE. Cisplatin, continuous-infusion 5-fluorouracil, and intermediate-dose methotrexate in the treatment of unresectable non-small cell carcinoma of the lung. Cancer. 1991 Feb 15; 67(4):892-5.
    View in: PubMed
  162. Kaye JA, Shulman LN. Screening program for colorectal cancer: Participation and follow-up. HMO Practice. 1991; 5:168-70.
  163. Shulman LN. Adjuvant therapy of colorectal cancer. Brigham and Women's Hospital: Medical Update. 1991; 3:1-5.
  164. Shulman LN. The acute leukemias. Rippe JM, Irwin RS, Alpert JS, Fink MP, eds. Intensive care medicine. 1991; 1070-5.
  165. Teicher BA, Herman TS, Shulman L, Bubley G, Coleman CN, Frei E. Combination of etanidazole with cyclophosphamide and platinum complexes. Cancer Chemother Pharmacol. 1991; 28(3):153-8.
    View in: PubMed
  166. Mitus AJ, Barbui T, Shulman LN, Rosenthal DS, Viero P, Cortelazzo S, Schafer AI. Hemostatic complications in young patients with essential thrombocythemia. Am J Med. 1990 Apr; 88(4):371-5.
    View in: PubMed
  167. Shulman LN, Zukerberg LR. Case records of the Massachusetts General Hospital. N Engl J Med. 1990; 322(1585):94.
  168. Leopold KA, Canellos GP, Rosenthal D, Shulman LN, Weinstein H, Mauch P. Stage IA-IIB Hodgkin's disease: staging and treatment of patients with large mediastinal adenopathy. J Clin Oncol. 1989 Aug; 7(8):1059-65.
    View in: PubMed
  169. Shulman LN, Bunn HF. Hb Deer Lodge in a Caucasian American: effect of iron deficiency on level of variant. Hemoglobin. 1988; 12(2):197-9.
    View in: PubMed
  170. Shulman L, Berwick DM, Caufield EA, Knapp ML. Detection of colorectal cancer. Am Fam Physician. 1986 Jan; 33(1):177-81.
    View in: PubMed
  171. Groopman JE, Hartzband PI, Shulman L, Salahuddin SZ, Sarngadharan MG, McLane MF, Essex M, Gallo R. Antibody seronegative human T-lymphotropic virus type III (HTLV-III)-infected patients with acquired immunodeficiency syndrome or related disorders. Blood. 1985 Sep; 66(3):742-4.
    View in: PubMed
  172. Raziuddin A, Sarkar FH, Dutkowski R, Shulman L, Ruddle FH, Gupta SL. Receptors for human alpha and beta interferon but not for gamma interferon are specified by human chromosome 21. Proc Natl Acad Sci U S A. 1984 Sep; 81(17):5504-8.
    View in: PubMed
  173. Shulman LN, Robinson SH. Transition from granulocyte to macrophage predominance in bone marrow cultures. Br J Haematol. 1983 Jul; 54(3):405-14.
    View in: PubMed
  174. Shulman LN, Robinson SH. Origin of multinucleated giant cells in long-term diffusion chamber cultures. Proc Soc Exp Biol Med. 1982 Jul; 170(3):359-62.
    View in: PubMed
  175. Shulman LN, Robinson SH. . Roles of CFU-S and CFU-C in maintaining cell growth in diffusion chamber cultures of murine marrow. Carsten AE, Cronkite EP, eds. Hemopoietic cell culture in diffusion chambers. 1980; 11-8.
  176. Revel M, Kimchi A, Shulman L, Fradin A, Shuster R, Yakobson E, Chernajovsky Y, Schmidt A, Shure A, Bendori R. Role of interferon-induced enzymes in the antiviral and antimitogenic effects of interferon. Ann N Y Acad Sci. 1980; 350:459-72.
    View in: PubMed
  177. Shulman LN, Robinson SH. Maintenance of hemopoietic stem cells in diffusion chamber cultures. J Lab Clin Med. 1977 Sep; 90(3):581-8.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Shulman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_